Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04442022 |
| Title | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Karyopharm Therapeutics Inc |
| Indications | |
| Therapies |
Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Selinexor |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | ESP | AUT |